Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M62.8Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-5.4
Enterprise Value $M29.6EPS (TTM) $-1.0Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score-4.2Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %-6.5Quick Ratio14.6Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-16.7Current Ratio14.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-107.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-179.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M31.7ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RNN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

RNN is held by these investors:



RNN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ahn Chang HoDirector 2017-04-10Sell25,000$7-71.71view
Jeong Tae HeumCFO 2015-01-12Sell31,727$9.1-78.24view
Ahn Chang HoDirector 2015-01-12Sell31,466$9.1-78.24view
Ahn Chang HoDirector 2014-06-12Sell13,619$9.9-80view
Jeong Tae HeumCFO 2013-09-09Sell7,114$4.6-56.96view
Kivel RichardDirector 2011-10-03Buy250$10.4-80.96view
Brandt Peter C.Director 2011-09-09Buy12,500$11.7-83.08view
Brandt Peter C.Director 2011-09-07Buy2,500$9.6-79.38view
Ahn Chang HoChairman & CEO, 10% Owner 2011-05-18Buy100,808$13.1-84.89view
Ahn Chang HoChairman & CEO, 10% Owner 2011-04-01Buy32,085$12.2-83.77view

Quarterly/Annual Reports about RNN:

News about RNN:

Articles On GuruFocus.com
Rexahn Announces $8 Million Registered Direct Offering Oct 13 2017 
Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Desi Oct 10 2017 
Rexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC Sep 21 2017 
Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New P Sep 11 2017 
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial Sep 10 2017 
Rexahn Pharmaceuticals to Present at 19th Annual Rodman & Renshaw Global Investment Conference Sep 06 2017 
Rexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society Sep 05 2017 
Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Dire Sep 01 2017 
Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™ Aug 30 2017 
Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Pla Aug 14 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK